Subscribe

Nykode Therapeutics AS (NYKD.OL)

NOK2.79 -0.03 (-0.89%)
NO OSL Healthcare Biotechnology
Address Oslo Research Park 349
Oslo, NO
CEO Michael Engsig
Website nykode.com
IPO 2020-10-07
ISIN NO0010714785

Explore sections of this company profile

Description

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
NOK2.79 -0.03 (-0.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
767.3K
Beta
0.84
Float Shares
170.88M
Free Float %
52.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-6.40% -3.82% +0.16% +8.82% +40.40% +33.26% +63.80% -88.59% -96.32% -94.84% -94.84%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.79
DCF (Unlevered) 1.57 -43.7%
DCF (Levered) 1.63 -41.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 +1
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
10.01
Safe zone
Piotroski F-Score
0 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -100.0% Q1'26: -100.0% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    +67.8% ★ Q1'26: -179.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    —
  • ✗
    EBIT margin Biotechnology: +0.0%
    —
  • ✗
    ROIC Biotechnology: -16.1%
    -88.6% Q1'26: -69.8% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.9% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.09× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.86) × ERP
WACC = 98% × Ke + 2% × Kd (5.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1.57 Current price: 2.79
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
2 Rev. Ana.
2 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
12.40M
est: 1.32M (+838.7%)
215.00M
est: 199.93M (+7.5%)
33.96M
est: 34.33M (-1.1%)
7.17M
est: 15.94M (-55.0%)
12.90M
est: 612.4K (+2,006.9%)
8.68M
est: 3.62M (+139.9%)
—
est: 776.5K (-100.0%)
189.3K
189.3K – 189.3K
-75.6% YoY
32.17M
32.17M – 32.17M
+16,895.5% YoY
18.38M
18.38M – 18.38M
-42.9% YoY
58.91M
58.91M – 58.91M
+220.5% YoY
EBITDA
-122.26M
est: -649.4K (-18,727.5%)
181.26M
est: -98.32M (+284.4%)
-10.25M
est: -16.88M (+39.3%)
-48.93M
est: -7.84M (-524.0%)
-41.74M
est: -281.9K (-14,705.4%)
-43.07M
est: -1.67M (-2,486.4%)
-27.84M
est: -357.5K (-7,688.8%)
-87.1K
-87.1K – -87.1K
+75.6% YoY
-14.81M
-14.81M – -14.81M
-16,895.5% YoY
-8.46M
-8.46M – -8.46M
+42.9% YoY
-27.12M
-27.12M – -27.12M
-220.5% YoY
EBIT
-122.39M
est: -655.4K (-18,572.9%)
180.95M
est: -99.24M (+282.3%)
-10.99M
est: -17.04M (+35.5%)
-50.74M
est: -7.91M (-541.1%)
-43.86M
est: -284.6K (-15,313.3%)
-45.33M
est: -1.68M (-2,596.2%)
-29.94M
est: -360.8K (-8,198.0%)
-88.0K
-88.0K – -88.0K
+75.6% YoY
-14.95M
-14.95M – -14.95M
-16,895.5% YoY
-8.54M
-8.54M – -8.54M
+42.9% YoY
-27.38M
-27.38M – -27.38M
-220.5% YoY
Net Income
-120.23M
est: -10.96M (-996.6%)
149.77M
est: 157.88M (-5.1%)
-9.41M
est: -9.67M (+2.6%)
-42.74M
est: -41.14M (-3.9%)
-35.15M
est: -3.63M (-867.5%)
-38.82M
est: -45.16M (+14.0%)
-12.60M
est: -11.79M (-6.9%)
-27.01M
-27.01M – -27.01M
-129.1% YoY
3.00M
2.68M – 3.32M
+111.1% YoY
-39.02M
-39.02M – -39.02M
-1,400.0% YoY
-42.02M
-42.02M – -42.02M
-7.7% YoY
SGA
54.38M
est: 671.0K (+8,004.4%)
8.56M
est: 101.60M (-91.6%)
9.28M
est: 17.44M (-46.8%)
8.89M
est: 8.10M (+9.7%)
6.28M
est: 428.8K (+1,364.1%)
4.35M
est: 2.53M (+71.5%)
14.00M
est: 543.7K (+2,475.2%)
132.5K
132.5K – 132.5K
-75.6% YoY
22.52M
22.52M – 22.52M
+16,895.6% YoY
12.87M
12.87M – 12.87M
-42.9% YoY
41.25M
41.25M – 41.25M
+220.5% YoY
EPS
-0.44
est: -0.03 (-1,198.2%)
0.51
est: 0.49 (+4.5%)
-0.04
est: -0.03 (-19.1%)
-0.15
est: -0.13 (-14.8%)
-0.12
est: -0.01 (-978.5%)
-0.12
est: -0.14 (+13.2%)
-0.04
est: -0.04 (-7.2%)
-0.08
-0.08 – -0.08
-129.1% YoY
0.01
0.01 – 0.01
+111.1% YoY
-0.12
-0.12 – -0.12
-1,400.0% YoY
-0.13
-0.13 – -0.13
-7.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-27 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-26 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-22 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-21 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-20 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-19 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-18 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-15 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-13 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-12 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-11 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-08 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-07 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-06 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-05 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-05-04 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-30 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-29 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-28 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-27 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-23 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-16 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-81.19M
OE per share TTM
-0.23
Owner's Yield
-7.89%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
15.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 3 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - International Small Cap ETF DFIS 0.00% 23.4K 0.39%
2 Dimensional - International Core Equity 2 ETF DFIC 0.00% 40.2K 0.22%
3 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 13.9K 0.28%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
Shares Outstanding
326.55M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Michael Thyring Engsig Chief Executive Officer 5M male
Agnete Fredriksen Co-Founder & Chief Scientific Officer — —
Harald Gurvin Chief Financial Officer — male
Louise Stubbe Chief Legal Officer — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology